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Abstract
Adenosine administration has been reported to lower blood pressure by activating specific membrane receptors. The rat
and human heart and aorta have been previously found to express both A2-type adenosine receptors, which activate adenylyl
cyclase, and A3 adenosine receptors (A3AR), which inhibit adenylyl cyclase. In the current study, we used A3 adenosine
receptor (A3AR) knock-out mice to examine the hypothesis that the relative levels of the A2-type adenosine receptors and
A3AR determine the steady-state levels of cAMP in the cells and may affect blood pressure. We found that the A3AR knock-
out mice express normal levels of the A1- and A2-type adenosine receptors. In situ hybridization demonstrated that the level
of A3AR is high in the vascular smooth muscle layer of aortas derived from wild-type mice, but is not detectable in the
knock-out mice. The steady-state level of cAMP is elevated in the aorta and heart of knock-out mice, as compared to wild-
type mice, but is not altered in platelets, where A3AR is not expressed naturally. A3AR knock-out mice possess a blood
pressure comparable to this in wild-type mice. However, when challenged with adenosine, the knock-out mice display a
further increase in cAMP levels in the heart and vascular smooth muscle and a significant decrease in blood pressure, as
compared to wild-type mice. In contrast, the effect of adenosine on ADP-induced platelet aggregation is similar in both types
of mice. These studies indicate that the A3AR affects the steady-state level of cAMP in the tissues where it is naturally
expressed, and that it influences the blood pressure in response to adenosine. ß 2000 Elsevier Science B.V. All rights
reserved.
1. Introduction
Adenosine, a metabolite of adenine nucleotides, is
released by facilitated di¡usion from metabolically
active cells and is generated by degradation of re-
leased ATP [1]. In addition to its biological role in
cellular metabolism, it has become clear that adeno-
sine plays an important physiological role in the car-
diovascular system. Adenosine receptors, members of
the superfamily of the G protein-coupled receptors,
have been classi¢ed into subtypes based on: (a) their
primary structure; (b) the secondary messenger sys-
tems to which they are coupled; and (c) the di¡er-
ential a⁄nities of a number of adenosine receptor
agonists and antagonists [2,3]. Based on these crite-
ria, four adenosine receptor (AR) subtypes have been
described: A1AR, A2aAR, A2bAR and A3AR.
These subtypes have been con¢rmed extensively by
cloning and functional characterization of rat, hu-
man, bovine and canine receptors [4]. The A3AR
has been detected in a number of tissues including
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the lung, heart and brain. Interestingly, striking dif-
ferences have been reported in tissue localization and
levels of A3AR transcripts between species [4]. In
humans, abundant transcripts have been found in
the liver, with moderate levels measured in heart,
aorta, kidney, lung and placenta [5].
The various physiological e¡ects of adenosine are
mediated through its activation of the above-de-
scribed speci¢c cell surface receptors. Adenosine
binding to the A1 or A3 adenosine receptors is
coupled to inhibition of adenylyl cyclase, while bind-
ing of this ligand to the A2-type (A2a or A2b) ad-
enosine receptors is coupled to the activation of ad-
enylyl cyclase [6,7]. Adenosine plays a major role in
regulating the balance of myocardial oxygen supply-
demand through its e¡ects on vascular tone [8]. Dur-
ing myocardial ischemia, adenosine is released in
large amounts and can exert potent, protective e¡ects
in the cardiovascular system [9^11]. For example,
vasoconstriction is attributed to A1 receptor activa-
tion [12], which also mediates the inhibition of renin
secretion [13]. Activation of A2 receptors is associ-
ated with renal vasodilation. Adenosine acting via
A2 receptors is also a potent coronary vasodilator
[14]. In some vascular beds, such as rabbit aorta
or canine femoral artery, adenosine exerts its
e¡ects in the absence of the endothelial layer [15],
indicating the importance of the direct smooth
muscle response. In accordance, administration to
rats of an adenosine analog which binds to A2 ad-
enosine receptors also lowers blood pressure and
heart rate [14].
Previously, we reported the expression of A3 ad-
enosine receptor mRNA in rat cultured vascular
smooth muscle cells (VSMC), and demonstrated
that a certain level of expression of the A3 adenosine
receptor mRNA is su⁄cient for attenuating adeno-
sine-induced increases in cAMP [16]. The detection
of A3AR mRNA in cultured VSMC corresponds
with its detection within total RNA of human aortas
[17]. Since activation of A2AR in VSMC has been
shown to induce vasodilation (reviewed in [9]), it
follows that the regulation of expression of the in-
hibitory A3AR in these cells is crucial for balanced
e¡ects of adenosine on cAMP and potentially on
blood pressure. In the current study, we used A3
adenosine receptor (A3AR) knock-out mice to exam-
ine the hypothesis that the relative levels of the A2-
type adenosine receptors and A3AR determines the
steady-state levels of cAMP in the cells and may
a¡ect blood pressure. We thus used A3AR knock-
out mice to investigate: (1) the expression of the
A3AR in smooth muscle of intact aortas; (2) the
contribution of A3 adenosine receptors to the
steady-state concentration of cAMP in aorta, heart,
and platelets; and (3) the e¡ects of adenosine on
blood pressure and platelet aggregation. Our data
indicate that the expression of A3AR in a tissue
does a¡ect the steady-state levels of cAMP in the
cells and that there is no linear correlation between
changes in cAMP levels in the heart or vascular
smooth muscle and blood pressure levels. Our data
point, however, to the importance of the A3AR in
determining blood pressure response to adenosine
administration.
2. Materials and methods
2.1. A3 adenosine receptor knock-out mice
The mouse A3 adenosine receptor gene was sub-
jected to homologous recombination leading to dis-
ruption of expression of A3 adenosine receptor
mRNA as described by [18]. These knock-out mice,
on a mixed background (C57BL/6/B6D2), were made
available to us by Dr. Marlene Jacobson at Merck
Research Laboratories (West Point, PA). The mice
were continuously bred with no di⁄culty and geno-
typed as follows: genomic DNA was digested with
BamHI and subjected to Southern blot analysis, us-
ing as a probe 750 base pairs (bp) of XhoI/HindIII
fragment isolated immediate upstream of the short
arm of the target construct [18]. The probe hybrid-
izes to a 3.1-kb band in the targeted allele (homozy-
gous knock-out); a 5.5-kb band in the endogenous
allele (wild-type) and both bands in heterozygous
animals. DNA preparation and Southern blot anal-
yses were performed essentially as we described be-
fore [19]. Mice de¢cient in the A3AR-subtype gene
and their wild-type controls were used in our studies.
The animals were 8 weeks old, weighing 26.2^32.8 g.
They were housed in the animal quarters with a 12-h
light/dark cycle and were provided food (Purina,
Certi¢ed Rodent Chow 5002) and distilled water ad
libitum. All experiments were conducted in accor-
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dance with the guidelines for the care and use of
animals approved by the Boston University Medical
Center.
2.2. Organ cultures, platelet preparation and cAMP
measurement
Aortas derived from age-matched (8-week-old)
and sex-matched (female) mice were isolated, washed
and extracted for cAMP determination by radioim-
munoassay, using appropriate controls for recovery
as we detailed before [16]. cAMP measurements were
also performed on platelets isolated from mouse
blood, as we described before [19]. When indicated,
platelets, at a concentration of 9U108/ml, were incu-
bated in a cAMP incubation bu¡er [16] for 5 min
with 1 WM forskolin (Sigma, St. Louis, MO) and/or
50 nM of the A3AR-selective agonist, N6-(3-iodo-
benzyl) adenosine-5P-N-methylcarboxamide (IB-
MECA) (RBI, Natick, MA). IB-MECA had no ef-
fect on cAMP levels in platelets in accordance with
the notion that these cells only possess the A2-type
adenosine receptors.
2.3. Platelet aggregation studies
Platelet aggregation studies in a platelet-rich plas-
ma were performed as described elsewhere [20]. Ad-
enosine-5P- diphosphate (ADP) (2 WM) (BIO/DATA,
Horsham, PA) was used to activate platelets in the
absence or presence of adenosine, as indicated by
changes in light-scattering monitored in a platelet
aggregometer (BIO/DATA, Horsham, PA).
2.4. Tail-cu¡ blood pressure and heart rate
measurements
To determine whether disruption of the A3AR
gene a¡ects blood pressure (BP) and heart rate
(HR) in these animals, tail-cu¡ systolic BP and HR
measurements were obtained in knock-out (A3AR
3/3), heterozygotes (A3AR +/3) and wild-type
(A3AR +/+) male and female mice. Tail-cu¡ systolic
blood pressure and heart rate measurements were
obtained using a computerized tail-cu¡ system (BP
2000 Visitech Systems, Apex, NC) [21]. The system
has the ability to determine systolic blood pressure
and heart rate in four mice simultaneously, and uses
a photoelectric sensor to detect the cu¡ pressure at
which blood £ow to the tail is eliminated. Mice were
trained for 5 consecutive days (each session consist-
ing of 20 unrecorded measurements) to familiarize
the animals to the tail-cu¡ apparatus. Subsequently,
blood pressure and heart rate measurements were
recorded daily for an additional 5 consecutive days.
Each session consisted of 20 measurements for each
mouse and the mean blood pressure and heart rate
for the day were calculated. Thus, the mean control
blood pressure and heart rate for each mouse were
obtained.
2.5. Adenosine infusion-catheterization
As adenosine has been shown to modulate several
cardiovascular functions, the e¡ect of adenosine ad-
ministration on BP was investigated in A3AR knock-
out mice and their wild-type controls. Arterial and
venous catheterization was performed in all age-
matched (8-week-old) female mice under anesthesia
induced by sodium pentobarbital (50 mg/kg, i.p.)
[22]. A modi¢ed polyethylene catheter (PE-50) was
introduced into the right iliac artery for direct blood
pressure (BP) recording and a silastic tubing was
placed into the right iliac vein for drug infusion.
Both catheters were tunneled subcutaneously and ex-
teriorized at the back of the animal’s neck. Subse-
quently, they were ¢lled with heparin in 0.9% saline
solution, sealed with heat and attached to the ani-
mal’s nape. After the surgery the animals were re-
turned in their cages and allowed an overnight recov-
ery period. On the following day, the arterial catheter
was connected to a BP transducer attached to a re-
corder (model 220S, Gould) for direct BP monitor-
ing. Control BP was recorded for no less than 30 min
or until the BP became stable. The venous catheter
was connected to a Harvard infusion pump and ad-
enosine was administered at a dose of 600 Wg/kg/min
for 60 min.
2.6. Statistical analysis
All data are presented as mean þ S.E.M. Student’s
t-test for paired and unpaired data was used, as ap-
propriate. The Mann^Whitney rank sum test was
used for non-parametric data. Di¡erences at
P6 0.05 were considered to be signi¢cant.
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2.7. In situ hybridization
A3AR knock-out and control mice were anesthe-
tized with methoxy£uorane and perfused with 4%
paraformaldehyde in phosphate-bu¡ered saline
(PBS). Aortas from these mice were ¢xed for an ad-
ditional 2 h in paraformaldehyde, followed by dehy-
dration in increasing concentrations of ethanol and
embedding in para⁄n. Sections of 5 Wm were a⁄xed
to slides and treated as described before [23]. Brie£y,
slides were depara⁄nized with xylene, washed in
ethanol, and rehydrated. Sections were then treated
with 20 Wg/ml proteinase K, acetylated by incubation
with acetic anhydride in 0.1 M triethanolamine, and
dehydrated once again. The probe used was derived
from the rat heart A3 adenosine receptor cDNA,
which we have derived by reverse transcription fol-
lowed by the polymerase chain reaction (RT-PCR)
on heart tissues, as we described before [16]. The
cDNA was con¢rmed by DNA sequencing and com-
parison to the published clone (GenBank accession
number M94152). Sense or antisense A3AR 35S-la-
beled riboprobes were prepared as described before
[24] and applied to the sections, which were subse-
quently covered with hybrislips and incubated for 16
h at 52‡C. Hybridized slides were washed in 50%
formamide/2USSC at 65‡C, followed by treatment
with RNase A (Sigma, St. Louis, MO). Subsequent
washes in 2U and 0.1USSC at 37‡C were followed
by dehydration and dipping in autoradiography
emulsion (Eastman Kodak, Rochester, NY). Follow-
ing development of the emulsion, slides were stained
with hematoxylin and eosin prior to analysis.
2.8. Northern blot analysis
RNA was extracted from di¡erent tissues derived
from wild-type and knock-out mice and subjected to
Northern blot analysis, as we described before
[16,19]. The blots were probed with the mouse
A3AR cDNA [25] or rat A2a or A2b or A1 adeno-
sine receptor cDNAs available to us [16]. The rat
clones were generated by RT-PCR of rat tissues, fol-
lowed by subcloning to a PUC-based vector and
DNA sequencing [19], to con¢rm the correct se-
quence. The sequences were compared to GenBank
Fig. 1. Expression of the A3AR in mouse aorta. Sections of an aorta derived from an A3AR knock-out mouse (A) or wild-type
mouse (B) were subjected to in situ hybridization using the mouse A3AR antisense riboprobe. The arrows point to stained nuclei. En,
endothelial cell nucleus; Sn, smooth muscle cell nucleus; El, elastic ¢ber; Lu, lumen.
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(accession numbers: rat A3AR cDNA, M94152; rat
A1AR cDNA, M69045; rat A2aAR cDNA, L08102;
rat A2bAR cDNA, M91466). In order to determine
equal loading of the samples to each lane, the blot
was also probed with an 18S ribosomal cDNA.
3. Results
3.1. Expression of A3 adenosine receptor in vascular
smooth muscle layer of aorta from wild-type and
knock-out mice
Expression of the A3AR in the aorta of rats and
humans was reported before [16,17]. However, it was
not clear if this receptor is indeed expressed in vas-
cular smooth muscle cells in vivo. The expression of
A3AR mRNA in the vascular smooth muscle layer
of the mouse aorta was demonstrated by in-situ hy-
bridization with an A3AR antisense riboprobe (Fig.
1). Interestingly, some A3AR mRNA was also de-
tected in the endothelial layer of the sectioned aorta.
In contrast, aortas derived from A3AR knock-out
mice completely lacked A3AR mRNA (Fig. 1). As
expected, no hybridization was detected with the
sense probe (data as in Fig. 1B). Similarly, Northern
blot analysis indicated that the A3AR knock-out
mice do not express A3AR mRNA in a variety of
tissues tested (data not shown), but the level of the
A1 or A2a or A2b adenosine receptor mRNA and
the pharmacological analyses (radioligand binding)
were similar in the knock-out and wild-type mice
(the tissues tested were: heart, aorta and liver) (our
unpublished data and [18]).
3.2. Steady-state levels of cAMP in aorta, heart and
platelets
As indicated above, the A3AR was reported be-
fore to be expressed, among other tissues, in heart
and aorta as well as in cultured rat vascular smooth
muscle cells. We recently demonstrated that an in-
verse correlation exists between the level of A3AR
mRNA in rat vascular smooth muscle cells in culture
and the intracellular level of cAMP, i.e. under con-
ditions where the expression of the A3 adenosine
receptor is reduced by antisense oligomers, a higher
level of cAMP is found in the cells [16]. Our current
study shows that the steady-state levels of cAMP are
signi¢cantly di¡erent in the aorta and heart from
wild-type and A3AR knock-out mice (Fig. 2). The
level of cAMP was signi¢cantly increased in aorta
and heart from A3AR knock-out mice relative to
wild-type controls. This relatively high base-line level
of cAMP in the A3AR knock-out mice could be
further elevated by the addition of adenosine. In
aortas of heterozygous A3AR knock-out mice, in
which only one allele was knocked out, the level of
cAMP was only increased by 10% as compared to
wild-type. These changes were subjected to statistical
analyses, as performed in Fig. 2, revealing that the
change was not statistically signi¢cant (not shown).
In the rest of the study, we thus focused on the
A3AR homozygous knock-out mice.
In platelets of wild-type mice, we found, there are
no active A3 adenosine receptors, as nanomolar con-
centrations of the A3AR selective agonist, IB-
MECA, had no inhibitory e¡ects on cAMP levels,
either in the absence or presence of 1 WM forskolin
(our unpublished data). When analyzed in platelets,
cells which express A2-type adenosine receptor [26],
there was no signi¢cant change in the steady-state
levels of cAMP between A3AR knock-out and nor-
mal mice. These results suggest a contribution of
Fig. 2. Levels of cAMP in aorta, heart and platelets of wild-
type and A3AR knock-out mice. Tissues from wild-type mice
(+/+) or A3AR knock-out mice (3/3) (control) were extracted
for cAMP measurements. When indicated, tissues were incu-
bated with 50 WM adenosine for 10 min prior to cAMP deter-
mination. Data are averages of four determinations with the in-
dicated standard deviation. The P-value of 6 0.05 (*) in a
group was considered to re£ect signi¢cant changes.
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A3AR to the regulation of the steady-state concen-
trations of cAMP within a tissue in which it is nat-
urally expressed.
3.3. Tail-cu¡ measurements of blood pressure
Table 1 summarizes mean tail-cu¡ blood pressure
(BP) and heart rate (HR) measurements in all groups
of mice. No di¡erence was found in either the BP
or HR between any of the groups studied (wild-type
+/+, heterozygotes +/3 or knock-out 3/3 mice),
nor was there a di¡erence between male and female
mice.
3.4. Changes in blood pressure in response to
adenosine
Fig. 3 presents BP changes during adenosine infu-
sion in A3AR +/+ (n = 8) and A3AR 3/3 (n = 8)
mice. Control BP was comparable in both groups,
averaging 107 þ 3.8 mmHg in A3AR +/+ and
104 þ 1.71 mmHg in A3AR 3/3 mice. Adenosine
administration at a dose of 600 Wg/kg/min resulted
in a signi¢cant BP reduction during the 60-min in-
fusion period in both wild-type (+/+) and knock-out
(3/3) animals. However, adenosine infusion resulted
in a signi¢cantly lower BP in the A3AR 3/3 mice,
Table 1
Tail-cu¡ systolic blood pressure and heart rate measurements in A3R +/+, A3R +/3 and A3R 3/3 male and female mice
Group A3R +/+ (n = 9) A3R +/3 (n = 7) A3R 3/3 (n = 7)
Male (n = 5) Female (n = 4) Male (n = 4) Female (n = 3) Male (n = 4) Female (n = 3)
BP (mmHg) 107.5 þ 3.76 103.8 þ 6.56 103.5 þ 0.96 102.5 þ 4.43 98.4 þ 5.44 107.7 þ 4.42
HR (beats/min) 618.4 þ 30.3 558.3 þ 22.3 606.2 þ 20.2 573.3 þ 23.8 656.8 þ 33.0 589.9 þ 7.6
All data are expressed as mean þ S.E.M. BP, blood pressure; HR, heart rate.
Fig. 3. Blood pressure changes in A3AR knock-out mice after infusion of adenosine intravenus (IV). Adenosine (at the indicated con-
centration) was infused in wild-type (+/+) or A3AR knock-out (3/3) mice and blood pressure was monitored at the indicated times.
Results are averages þ S.E.M. for eight mice.
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as compared to their wild-type counterparts. This
di¡erence in BP reduction was evident within the ¢rst
minutes of infusion and persisted throughout the 60-
min infusion period. Moreover, after the discontinu-
ation of adenosine infusion, A3AR +/+ mice re-
turned to the pre-infusion BP levels faster than their
knock-out (3/3) counterparts. It was not technically
possible to monitor the HR in these infused mice.
3.5. Platelet activation studies
As indicated above, cAMP levels in platelets of
wild-type and A3AR knock-out mice was quite com-
parable. In accordance, the extent of inhibition by
adenosine (used in the range of 1^40 WM) of ADP-
induced aggregation was comparable in both types of
mice. Fig. 4 shows a result of a representative experi-
ment, using 10 WM adenosine. This suggests that the
magnitude of adenosine e¡ect is not altered, as com-
pared to control, in a cell type where the A3AR is
not normally expressed.
4. Discussion
In mammalian tissues, adenosine can be formed
through de-novo synthesis or from a variety of sub-
strates (reviewed by [27]). The intracellular level of
adenosine, determined by the balance of its produc-
tion and metabolism, is about 15 WM in most cells
tested under normal conditions, and can rise to much
higher concentrations during stress, such as ischemia
or anoxia [28]. The origin of adenosine in the blood
can be traced to intracellular adenosine released from
cells via a nucleoside transport system, as well as to
the activity of ectoenzymes, such as ecto-5P-nucleoti-
dase [28,29]. Aggregating platelets as well as endo-
thelial cells release ADP and ATP, which can be
converted to adenosine by ectoenzymes on endothe-
lial or cardiac cells [28,29]. Adenosine exerts its ef-
fects via binding to speci¢c adenosine receptors
which modulate adenylyl cyclase activity as well as
signaling pathways, such as phospholipase C, in the
case of A3AR activation. In some tissues, such as
heart and aorta, adenylyl cyclase-inhibitory (A1-
and A3-types), as well as adenylyl cyclase stimula-
tory receptors (A2-type) are co-expressed [16,27]. Ef-
fects of adenosine in the cardiovascular system may
stem from the renal and cardiovascular tissues. The
response to adenosine in kidney is biphasic, with an
initial transient vasoconstriction being followed by
dilation [13]. Vasoconstriction is attributed to A1
receptor activation [12], which also mediates the in-
hibition of renin secretion [13]. Adenosine also plays
a central role in ischemia-reperfusion injury. Under
these conditions there is an increase in coronary ves-
sel adenosine levels as a result of ATP degradation
[30]. Tissue damage occurs via free radicals and mod-
Fig. 4. Adenosine-induced changes in platelet aggregration. Platelet-rich plasma derived from wild-type (1,2) or A3AR knock-out mice
(3,4) were induced to aggregate with 2 WM ADP (indicated by an arrow) in the absence (1,3) or presence of 10 WM adenosine (2,4).
The data shown are of a representative set out of two di¡erent experiments, each with two sets of mice per group.
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ulators of the in£ammatory response [31]. Local in-
tracoronary infusions of adenosine at the time of
reperfusion can reduce myocardial necrosis, endothe-
lial damage, and granulocyte accumulation [32].
Also, adenosine administration lowers blood pres-
sure and heart rate [14,33]. Of the many e¡ects of
adenosine in the cardiovascular system, we elected to
focus in the current study on exploring the impor-
tance of adenosine-mediated activation of A3AR for
maintenance of blood pressure, by analysis of A3AR
knock-out mice.
We found that the vascular smooth muscle tissue
in aortas of wild-type mice express high levels of the
A3AR, while as expected, no expression was found
in the knock-out mice. Also, Northern blot analysis
indicated that A3AR mRNA is not found in a vari-
ety of tissues derived from the A3AR knock-out
mice, while the levels of the A1, A2a and A2b ad-
enosine receptor mRNAs was similar in heart and
aorta of the knock-out and the wild-type mice.
This may rule out the possibility that the changes
observed in physiological parameters in the A3AR
knock-out mice are due to a secondary e¡ect on
other adenosine receptors. The blood pressure is sim-
ilar in the A3AR knock-out and wild-type mice.
However, when challenged with adenosine, the
knock-out mice display a signi¢cant decrease in
blood pressure, as compared to wild-type mice. Our
¢ndings suggest that under normal adenosine con-
centrations, the A3-type adenosine receptors are
not active in mediating changes in blood pressure
and that they are overpowered by A2AR receptors
that mediate signals for vasodilation. It is important
to note in this regard that the a⁄nity of adenosine to
the A2-type receptors is higher by an order of mag-
nitude than the a⁄nity to the A3AR [34]. In a study
by Shepherd et al., the vasomotor e¡ects of adeno-
sine were analyzed by following changes in the diam-
eters of microvessels in hamster cheek pouches [35].
This study led to the conclusion that ligands binding
to the mast cell A3 adenosine receptors mediate de-
granulation as well as vasoconstriction. Interestingly,
it was also concluded that adenosine initiates multi-
ple con£icting vasomotor signals, as A2 adenosine
receptor-mediated dilation was competing with con-
striction (with the A2AR overpowering the A3AR),
and thus adenosine analogs, but not adenosine, were
able to induce changes in mast cell activation.
In contrast to the e¡ect of adenosine on blood
pressure, the e¡ect of this ligand on ADP-induced
platelet aggregation was similar in both the wild-
type and A3AR knock-out mice. The e¡ect of ad-
enosine on this cell type was examined since we
found that platelets do possess signi¢cant levels of
an active A3AR. This leads us to speculate that the
magnitude and nature of adenosine e¡ect depends on
the ability of tissues to co-express the stimulatory
and inhibitory adenosine receptors. This hypothesis
will await further examination in mice lacking other
types of adenosine receptors.
Adenosine actions in di¡erent systems are essen-
tially of two types: those that are cAMP dependent,
and others that are cAMP independent. Activation
of SA, atrial, and AV nodal adenosine receptors re-
sults in activation of a speci¢c outward potassium
current, which is cAMP independent [36,37]. In ven-
tricular myocytes, adenosine antagonizes the stimu-
latory actions of catecholamines on ICa and on the
transient inward current [38]. This antagonism by
adenosine and its analogs is due to the inhibition
of adenylyl cyclase [39,40]. Adenosine and its analogs
also inhibit ADP-induced platelet aggregation, de-
pendent on activation of adenylyl cyclase [41,42].
Several pathways have been proposed to explain
the mechanism of action of adenosine in various tis-
sues: (1) modulation of adenylyl cyclase activity, as
also observed with the adrenergic receptors [43]; (2)
modulation of Ca2 channel activity, e.g., adenosine
inhibits Ca2 uptake in heart [44] ; (3) modulation of
K conductance, e.g. in pig atria adenosine causes an
increase in potassium conductance, which could ex-
plain the shortening of the action potential duration
and hyperpolarization caused by adenosine [45]; and
(4) modulation of phospholipase C activity which
may a¡ect intracellular Ca2 concentrations [46].
In the current study, we focused on changes in
cAMP levels in wild-type and in A3AR knock-out
mice, as this is one of the immediate change occur-
ring upon A3AR receptor activation. In platelets, in
which this receptor is not naturally expressed, there
is no change in cAMP levels as compared to wild-
type mice or in platelet aggregation in response to
adenosine. While several studies have directly linked
changes in cAMP levels in aorta and heart to blood
pressure values, the increase in cAMP is not directly
associated with low blood pressure and vice versa
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[47^53]. We found that in the A3AR knock-out mice,
the steady-state level of cAMP is elevated in aortas
and heart, as compared to wild-type mice, with no
change in blood pressure level. Further elevation of
cAMP in these tissues from A3AR knock-out mice
treated with adenosine was associated with an in-
crease in blood pressure. Our study thus leads to
the important conclusions that the presence of
A3AR has a signi¢cant impact on the steady-state
levels of cAMP in the cells, and hence potentially
on a variety of cAMP-dependent processes, and
that adenosine-mediated e¡ects on blood pressure
are not directly correlated with changes in the levels
of cAMP. With the lack of a reliable technique to
monitor changes in Ca2 in an intact aorta of a
mouse, we are forced to postponed these experi-
ments. As described above, based on the studies by
Shepherd et al., which were done with adenosine
analogs binding to A3AR, one may speculate that
adenosine treatment of A3AR knock-out mice will
result in a less e¡ective degranulation of mast cells
and attenuated release of vasoconstricting substan-
ces, a process which may contribute to vascular
changes [35]. We could not examine this possibility
of attenuation in comparison to wild-type mast cells,
as adenosine does not activate these latter cells be-
cause of the overpowering e¡ect of the A2AR [35].
The role of mast cells in vasoconstriction and in
determining blood pressure will have to be deter-
mined in A2AR knock-out mice.
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